J. B. Calixto, M. M. Campos, M. F. Otuki, and A. R. Santos, Anti-inflammatory compounds of plant origin. Part II. modulation of pro-inflammatory cytokines, chemokines and adhesion molecules, Planta Med, vol.70, pp.93-103, 2004.

J. B. Calixto, M. F. Otuki, and A. R. Santos, Anti-inflammatory compounds of plant origin. Part I. Action on arachidonic acid pathway, nitric oxide and nuclear factor kappa B (NF-kappaB), Planta Med, vol.69, pp.973-983, 2003.

C. Bailly, Ready for a comeback of natural products in oncology, Biochem Pharmacol, vol.77, pp.1447-1457, 2009.
URL : https://hal.archives-ouvertes.fr/hal-00493481

M. A. Medina, B. Martinez-poveda, M. I. Amores-sanchez, and A. R. Quesada, Hyperforin: more than an antidepressant bioactive compound?, Life Sci, vol.79, pp.105-111, 2006.

C. Quiney, C. Billard, C. Salanoubat, J. D. Fourneron, and J. P. Kolb, Hyperforin, a new lead compound against the progression of cancer and leukemia, Leukemia, vol.20, pp.1519-1525, 2006.

F. Borrelli and A. A. Izzo, Herb-drug interactions with St John's wort (Hypericum perforatum): an update on clinical observations, Aaps J, vol.11, pp.710-727, 2009.

T. N. Griffith, L. Varela-nallar, M. C. Dinamarca, and N. C. Inestrosa, Neurobiological effects of Hyperforin and its potential in Alzheimer's disease therapy, Curr Med Chem, vol.17, pp.391-406, 2010.

C. Feisst, C. Pergola, M. Rakonjac, A. Rossi, and A. Koeberle, Hyperforin is a novel type of 5-lipoxygenase inhibitor with high efficacy in vivo, Cell Mol Life Sci, vol.66, pp.2759-2771, 2009.

I. Dell'aica, R. Caniato, S. Biggin, and S. Garbisa, wort: biomedical research catches up with folk medicine, Clin Chim Acta, vol.381, pp.69-77, 2007.

G. Lorusso, N. Vannini, I. Sogno, L. Generoso, and S. Garbisa, Mechanisms of Hyperforin as an anti-angiogenic angioprevention agent, Eur J Cancer, vol.45, pp.1474-1484, 2009.

M. Rothley, A. Schmid, W. Thiele, V. Schacht, and D. Plaumann, Hyperforin and aristoforin inhibit lymphatic endothelial cell proliferation in vitro and suppress tumor-induced lymphangiogenesis in vivo, Int J Cancer, vol.125, pp.34-42, 2009.

K. Hostanska, J. Reichling, S. Bommer, M. Weber, and R. Saller, Hyperforin a constituent of St John's wort (Hypericum perforatum L.) extract induces apoptosis by triggering activation of caspases and with hypericin synergistically exerts cytotoxicity towards human malignant cell lines, Eur J Pharm Biopharm, vol.56, pp.121-132, 2003.

J. Y. Liu, Z. Liu, D. M. Wang, M. M. Li, and S. X. Wang, Induction of apoptosis in K562 cells by dicyclohexylammonium salt of hyperforin through a mitochondrial-related pathway, Chem Biol Interact, vol.190, pp.91-101, 2011.

C. Quiney, C. Billard, A. M. Faussat, C. Salanoubat, and A. Ensaf, Proapoptotic properties of hyperforin in leukemic cells from patients with B-cell chronic lymphocytic leukemia, Leukemia, vol.20, pp.491-497, 2006.

M. Zaher, I. Akrout, M. Mirshahi, J. P. Kolb, and C. Billard, Noxa upregulation is associated with apoptosis of chronic lymphocytic leukemia cells induced by hyperforin but not flavopiridol, Leukemia, vol.23, pp.594-596, 2009.

M. E. King and J. M. Rowe, Recent developments in acute myelogenous leukemia therapy, Oncologist, vol.12, issue.2, pp.14-21, 2007.

K. D. Mason, S. K. Juneja, and J. Szer, The immunophenotype of acute myeloid leukemia: is there a relationship with prognosis?, Blood Rev, vol.20, pp.71-82, 2006.

C. Plesa, Y. Chelghoum, A. Plesa, M. Elhamri, and I. Tigaud, Prognostic value of immunophenotyping in elderly patients with acute myeloid leukemia: a single-institution experience, Cancer, vol.112, pp.572-580, 2008.

E. W. Newcomb, Flavopiridol: pleiotropic biological effects enhance its anticancer activity, Anticancer Drugs, vol.15, pp.411-419, 2004.

Z. B. Wang, Y. Q. Liu, and Y. F. Cui, Pathways to caspase activation, Cell Biol Int, vol.29, pp.489-496, 2005.

E. A. Afanasyeva, E. Y. Komarova, L. G. Larsson, F. Bahram, and B. A. Margulis, Drug-induced Myc-mediated apoptosis of cancer cells is inhibited by stress protein Hsp70, Int J Cancer, vol.121, pp.2615-2621, 2007.

R. R. Rosato, J. A. Almenara, S. S. Kolla, S. C. Maggio, and S. Coe, Mechanism and functional role of XIAP and Mcl-1 down-regulation in flavopiridol/vorinostat antileukemic interactions, Mol Cancer Ther, vol.6, pp.692-702, 2007.

D. M. Lucas, R. B. Edwards, G. Lozanski, D. A. West, and J. D. Shin, The novel plant-derived agent silvestrol has B-cell selective activity in chronic lymphocytic leukemia and acute lymphoblastic leukemia in vitro and in vivo, Blood, vol.113, pp.4656-4666, 2009.

G. Song, G. G. Chen, T. Hu, and P. B. Lai, Bid Stands at the Crossroad of Stressresponse Pathways, Curr Cancer Drug Targets, vol.10, pp.584-592, 2010.

A. M. Martelli, M. Nyakern, G. Tabellini, R. Bortul, and P. L. Tazzari, Phosphoinositide 3-kinase/Akt signaling pathway and its therapeutical implications for human acute myeloid leukemia, Leukemia, vol.20, pp.911-928, 2006.

S. Zhao, M. Konopleva, M. Cabreira-hansen, Z. Xie, and W. Hu, Inhibition of phosphatidylinositol 3-kinase dephosphorylates BAD and promotes apoptosis in myeloid leukemias, Leukemia, vol.18, pp.267-275, 2004.

S. R. Datta, A. Brunet, and M. E. Greenberg, Cellular survival: a play in three Akts, Genes Dev, vol.13, pp.2905-2927, 1999.

Y. Dai, M. Rahmani, X. Y. Pei, P. Dent, and S. Grant, Bortezomib and flavopiridol interact synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to imatinib mesylate through both Bcr/Abl-dependent and -independent mechanisms, Blood, vol.104, pp.509-518, 2004.

Y. Takada, G. Sethi, B. Sung, and B. B. Aggarwal, Flavopiridol suppresses tumor necrosis factor-induced activation of activator protein-1, c-Jun N-terminal kinase, p38 mitogen-activated protein kinase (MAPK), p44/p42 MAPK, and Akt, inhibits expression of antiapoptotic gene products, and enhances apoptosis through cytochrome c release and caspase activation in human myeloid cells, Mol Pharmacol, vol.73, pp.1549-1557, 2008.

T. Braun, G. Carvalho, C. Fabre, J. Grosjean, and P. Fenaux, Targeting NF-kappaB in hematologic malignancies, Cell Death Differ, vol.13, pp.748-758, 2006.

J. Mathieu, S. Giraudier, M. Lanotte, and F. Besancon, Retinoid-induced activation of NF-kappaB in APL cells is not essential for granulocytic differentiation, but prolongs the life span of mature cells, Oncogene, vol.24, pp.7145-7155, 2005.

C. Scaffidi, I. Schmitz, J. Zha, S. J. Korsmeyer, and P. H. Krammer, Differential modulation of apoptosis sensitivity in CD95 type I and type II cells, J Biol Chem, vol.274, pp.22532-22538, 1999.

L. P. Billen, A. Shamas-din, and D. W. Andrews, Bid: a Bax-like BH3 protein, Oncogene, vol.27, issue.1, pp.93-104, 2008.

R. H. Decker, S. Wang, Y. Dai, P. Dent, and S. Grant, Loss of the Bcl-2 phosphorylation loop domain is required to protect human myeloid leukemia cells from flavopiridol-mediated mitochondrial damage and apoptosis, Cancer Biol Ther, vol.1, pp.136-144, 2002.

C. Park, C. Y. Jin, G. Y. Kim, I. W. Choi, and T. K. Kwon, Induction of apoptosis by esculetin in human leukemia U937 cells through activation of JNK and ERK, Toxicol Appl Pharmacol, vol.227, pp.219-228, 2008.

E. Bremer, G. Van-dam, B. J. Kroesen, L. De-leij, and W. Helfrich, Targeted induction of apoptosis for cancer therapy: current progress and prospects, Trends Mol Med, vol.12, pp.382-393, 2006.

C. Ploner, R. Kofler, and A. Villunger, Noxa: at the tip of the balance between life and death, Oncogene, vol.27, issue.1, pp.84-92, 2009.

S. Dalle, J. Quoyer, E. Varin, and S. Costes, Roles and Regulation of the Transcription Factor CREB in Pancreatic b-Cells, Curr Mol Pharmacol, 2011.

S. Maddika, S. R. Ande, S. Panigrahi, T. Paranjothy, and K. Weglarczyk, Cell survival, cell death and cell cycle pathways are interconnected: implications for cancer therapy, Drug Resist Updat, vol.10, pp.13-29, 2007.

Y. Liao and M. C. Hung, Physiological regulation of Akt activity and stability, Am J Transl Res, vol.2, pp.19-42, 2010.

J. Z. Qin, L. Stennett, P. Bacon, B. Bodner, and M. J. Hendrix, independent NOXA induction overcomes apoptotic resistance of malignant melanomas, Mol Cancer Ther, vol.3, pp.895-902, 2004.

T. Stankovic, M. Hubank, D. Cronin, G. S. Stewart, and D. Fletcher, Microarray analysis reveals that TP53-and ATM-mutant B-CLLs share a defect in activating proapoptotic responses after DNA damage but are distinguished by major differences in activating prosurvival responses, Blood, vol.103, pp.291-300, 2004.

A. M. Martelli, L. Cocco, S. Capitani, S. Miscia, and S. Papa, Nuclear phosphatidylinositol 3,4,5-trisphosphate, phosphatidylinositol 3-kinase, Akt, and PTen: emerging key regulators of anti-apoptotic signaling and carcinogenesis, Eur J Histochem, vol.51, issue.1, pp.125-131, 2007.

Z. Zeng, D. Sarbassov-dos, I. J. Samudio, K. W. Yee, and M. F. Munsell, Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML, Blood, vol.109, pp.3509-3512, 2007.

N. Chapuis, J. Tamburini, A. S. Green, L. Willems, and V. Bardet, Perspectives on inhibiting mTOR as a future treatment strategy for hematological malignancies, Leukemia, vol.24, pp.1686-1699, 2010.

V. Calleja, M. Laguerre, P. J. Parker, and B. Larijani, Role of a novel PH-kinase domain interface in PKB/Akt regulation: structural mechanism for allosteric inhibition, PLoS Biol, vol.7, pp.189-200, 2009.

I. Hers, E. E. Vincent, and J. M. Tavare, Akt signalling in health and disease, Cell Signal, 2011.

S. F. Barnett, D. Defeo-jones, S. Fu, P. J. Hancock, and K. M. Haskell, Identification and characterization of pleckstrin-homology-domain-dependent and isoenzyme-specific Akt inhibitors, Biochem J, vol.385, pp.399-408, 2005.

H. H. Sedlacek, Mechanisms of action of flavopiridol, Crit Rev Oncol Hematol, vol.38, pp.139-170, 2001.

Y. Takada and B. B. Aggarwal, Flavopiridol inhibits NF-kappaB activation induced by various carcinogens and inflammatory agents through inhibition of IkappaBalpha kinase and p65 phosphorylation: abrogation of cyclin D1, cyclooxygenase-2, and matrix metalloprotease-9, J Biol Chem, vol.279, pp.4750-4759, 2004.

F. J. Giles and M. Albitar, Mammalian target of rapamycin as a therapeutic target in leukemia, Curr Mol Med, vol.5, pp.653-661, 2005.

A. Peng and J. L. Maller, Serine/threonine phosphatases in the DNA damage response and cancer, Oncogene, vol.29, pp.5977-5988, 2010.

T. A. Millward, S. Zolnierowicz, and B. A. Hemmings, Regulation of protein kinase cascades by protein phosphatase 2A, Trends Biochem Sci, vol.24, pp.186-191, 1999.

M. Yamamoto, Y. Suzuki, H. Kihira, H. Miwa, and K. Kita, Expressions of four major protein Ser/Thr phosphatases in human primary leukemic cells, Leukemia, vol.13, pp.595-600, 1999.

I. Cristobal, L. Garcia-orti, C. Cirauqui, M. M. Alonso, and M. J. Calasanz, PP2A impaired activity is a common event in acute myeloid leukemia and its activation by forskolin has a potent anti-leukemic effect, Leukemia, vol.25, pp.606-614, 2011.

J. S. Duncan, J. P. Turowec, G. Vilk, S. S. Li, and G. B. Gloor, Regulation of cell proliferation and survival: convergence of protein kinases and caspases, Biochim Biophys Acta, vol.1804, pp.505-510, 2010.

B. Z. Carter, D. H. Mak, W. D. Schober, M. F. Dietrich, and C. Pinilla, Triptolide sensitizes AML cells to TRAIL-induced apoptosis via decrease of XIAP and p53-mediated increase of DR5, Blood, vol.111, pp.3742-3750, 2008.

L. Guan, F. Huang, Z. Li, B. Han, and Q. Jiang, P53 transcriptionindependent activity mediates selenite-induced acute promyelocytic leukemia NB4 cell apoptosis, BMB Rep, vol.41, pp.745-750, 2008.

K. Sugimoto, H. Toyoshima, R. Sakai, K. Miyagawa, and K. Hagiwara, Frequent mutations in the p53 gene in human myeloid leukemia cell lines, Blood, vol.79, pp.2378-2383, 1992.

D. Cilloni, G. Martinelli, F. Messa, M. Baccarani, and G. Saglio, Nuclear factor kB as a target for new drug development in myeloid malignancies, Haematologica, vol.92, pp.1224-1229, 2007.

P. Zanoli, Role of hyperforin in the pharmacological activities of, CNS Drug Rev, vol.10, pp.203-218, 2004.

H. U. Schulz, M. Schurer, D. Bassler, and D. Weiser, Investigation of the bioavailability of hypericin, pseudohypericin, hyperforin and the flavonoids quercetin and isorhamnetin following single and multiple oral dosing of a hypericum extract containing tablet, Arzneimittelforschung, vol.55, pp.15-22, 2005.

M. Wurglics and M. Schubert-zsilavecz, Hypericum perforatum: a 'modern' herbal antidepressant: pharmacokinetics of active ingredients, Clin Pharmacokinet, vol.45, pp.449-468, 2006.

W. Stock, Controversies in treatment of AML: case-based discussion, Hematology Am Soc Hematol Educ Program, pp.185-191, 2006.

S. V. Ambudkar, S. Dey, C. A. Hrycyna, M. Ramachandra, and I. Pastan, Biochemical, cellular, and pharmacological aspects of the multidrug transporter, Annu Rev Pharmacol Toxicol, vol.39, pp.361-398, 1999.

P. Sonneveld and A. F. List, Chemotherapy resistance in acute myeloid leukaemia, Best Pract Res Clin Haematol, vol.14, pp.211-233, 2001.

C. Quiney, C. Billard, A. M. Faussat, C. Salanoubat, and J. P. Kolb, Hyperforin inhibits P-gp and BCRP activities in chronic lymphocytic leukaemia cells and myeloid cells, Leuk Lymphoma, vol.48, pp.1587-1599, 2007.

Y. Komeno, J. Kitaura, and T. Kitamura, Molecular bases of myelodysplastic syndromes: lessons from animal models, J Cell Physiol, vol.219, pp.529-534, 2009.

M. G. Kharas, R. Okabe, J. J. Ganis, M. Gozo, and T. Khandan, Constitutively active AKT depletes hematopoietic stem cells and induces leukemia in mice, Blood, vol.115, pp.1406-1415, 2010.

A. Stoddart, T. R. Tennant, A. A. Fernald, J. Anastasi, and F. M. Brodsky, The clathrin-binding domain of CALM-AF10 alters the phenotype of myeloid neoplasms in mice, Oncogene, 2011.

A. M. Martelli, C. Evangelisti, F. Chiarini, C. Grimaldi, and L. Manzoli, Targeting the PI3K/AKT/mTOR signaling network in acute myelogenous leukemia, Expert Opin Investig Drugs, vol.18, pp.1333-1349, 2009.

E. J. Meuillet, Novel Inhibitors of AKT: Assessment of a Different Approach Targeting the Pleckstrin Homology Domain, Curr Med Chem, 2011.

H. Quentmeier, M. P. Martelli, W. G. Dirks, N. Bolli, and A. Liso, Cell line OCI/AML3 bears exon-12 NPM gene mutation-A and cytoplasmic expression of nucleophosmin, Leukemia, vol.19, pp.1760-1767, 2005.

M. Lanotte, V. Martin-thouvenin, S. Najman, and P. Balerini, NB4, a maturation inducible cell line with t(15;17) marker isolated from a human acute promyelocytic leukemia (M3), Blood, vol.77, pp.1080-1086, 1991.

J. D. Fourneron and Y. Naït-si, Effect of eluent pH on HPLC/UV analysis of hyperforin, Phytochem Anal, vol.17, pp.71-77, 2006.

A. Bhardwaj, G. Sethi, S. Vadhan-raj, C. Bueso-ramos, and Y. Takada, Resveratrol inhibits proliferation, induces apoptosis, and overcomes chemoresistance through down-regulation of STAT3 and nuclear factor-kappaBregulated antiapoptotic and cell survival gene products in human multiple myeloma cells, Blood, vol.109, pp.2293-2302, 2007.

Y. R. Kim, N. G. Abraham, and J. D. Lutton, Mechanisms of differentiation of U937 leukemic cells induced by GM-CSF and 1,25(OH)2 vitamin D3, Leuk Res, vol.15, pp.409-418, 1991.

I. D. Trayner, T. Bustorff, A. E. Etches, G. J. Mufti, and Y. Foss, Changes in antigen expression on differentiating HL60 cells treated with dimethylsulphoxide, all-trans retinoic acid, alpha1,25-dihydroxyvitamin D3 or 12-Otetradecanoyl phorbol-13-acetate, Leuk Res, vol.22, pp.537-547, 1998.

B. Bauvois, J. Van-weyenbergh, D. Rouillard, and J. Wietzerbin, TGF-beta 1-stimulated adhesion of human mononuclear phagocytes to fibronectin and laminin is abolished by IFN-gamma: dependence on alpha 5 beta 1 and beta 2 integrins, Exp Cell Res, vol.222, pp.209-217, 1996.

J. Sanceau, D. D. Boyd, M. Seiki, and B. Bauvois, Interferons inhibit tumor necrosis factor-alpha-mediated matrix metalloproteinase-9 activation via interferon regulatory factor-1 binding competition with NF-kappa B, J Biol Chem, vol.277, pp.35766-35775, 2002.